GlassScriptPhysician profile
Rajankumar P Patel
NPI 1396896023
$3,862.97
in general payments reported to CMS, 2019-2025
26 companies · $383 in 2025
The $383 reported for 2025 was more than what 78% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $227 · 2021: $914 · 2022: $1,145 · 2023: $455 · 2024: $452 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.66 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $758.39 | 2020-2025 | |
| Novo Nordisk INC | $709.39 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $666.80 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $338.75 | 2019-2023 | Mounjaro |
| Abbott Laboratories | $325.15 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.26 | 2021-2025 | Jardiance, Tradjenta |
| Amgen INC. | $130.55 | 2022-2024 | Repatha, Otezla, Evenity |
| Shield Therapeutics INC | $99.94 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.19 | 2021-2024 | |
| Pfizer INC. | $76.43 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $43.33 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.76 | 2020-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $39.83 | 2022 | |
| Merck Sharp & Dohme LLC | $28.36 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.99 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $27.77 | 2021-2023 | Gvoke Hypopen |
| Genentech USA, INC. | $24.90 | 2021-2022 | |
| Biogen, INC. | $24.86 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.64 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $17.78 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $16.62 | 2021 | |
| Althera Pharmaceuticals LLC | $14.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.10 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.76 | 2022 | |
| Clarus Therapeutics INC. | $10.95 | 2021 | |
| Phathom Pharmaceuticals, INC. | $7.98 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajankumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.